▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Lawler

brian-lawler

Recent Articles by Brian Lawler

Nov 14, 2016 by Brian Lawler

Elan Gets a Vote of Confidence

Elan receives a recommendation to expand the use of Tysabri.

Nov 14, 2016 by Brian Lawler

Calling Out Endo

Endo gets taken to task by an activist investor.

Nov 14, 2016 by Brian Lawler

Avandia Can Stay

The FDA votes to allow GSK's top diabetes compound to remain on the market.

Nov 14, 2016 by Brian Lawler

Amgen Adjusting

Amgen's second quarter reflects the pain it's feeling with its top drugs.

Nov 14, 2016 by Brian Lawler

AstraZeneca's Yawner of a Quarter

The pharma company's Q2 results are ho-hum.

Nov 14, 2016 by Brian Lawler

Bristol-Myers Isn't Standing in Place

The final quarter of stagnating financials for Bristol-Myers.

Nov 14, 2016 by Brian Lawler

AtheroGenics Follows a New Route

AtheroGenics gives more details on the path forward for its lead drug.

Nov 14, 2016 by Brian Lawler

The Good and Bad of Elan

Elan has had a busy July.

Nov 14, 2016 by Brian Lawler

Is Glaxo's Avandia Down for the Count?

An FDA advisory committee is set to debate one of Glaxo's top compounds.

Nov 14, 2016 by Brian Lawler

Jumpstarting Genzyme

Genzyme has a good second quarter.

Nov 14, 2016 by Brian Lawler

Millennium Waits for the Future

Millennium releases its second-quarter financial results.

Nov 14, 2016 by Brian Lawler

Glaxo Getting Through Avandia Loss

Glaxo's earnings aren't hurt by the decline in Avandia sales.

Nov 14, 2016 by Brian Lawler

Exelixis Goes It Alone

Partner Glaxo passes on codeveloping a new cancer drug.

Nov 14, 2016 by Brian Lawler

Flamel Gets Stomped by GSK

Shares of Flamel fall as its partner doesn't focus on marketing its lead drug.

Nov 14, 2016 by Brian Lawler

Lilly Doesn't Wilt

The second quarter was another good one for Eli Lilly.

Nov 14, 2016 by Brian Lawler

GPC Must Wait

An advisory panel recommends against approving GPC's lead drug right now.

Nov 14, 2016 by Brian Lawler

Vertex Is on Its Way

Vertex highlights what's ahead for the rest of the year.

Nov 14, 2016 by Brian Lawler

Discounting InterMune

Shares of InterMune fall after analyst worries about one of its drugs.

Nov 14, 2016 by Brian Lawler

MGI Flies

Shares of MGI Pharma rise after positive second-quarter results.

Nov 14, 2016 by Brian Lawler

Pain and Alpharma Gain From Purdue's Slip

Some drugmakers gain from the government's admonishment of Purdue.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services